Royal Bank Of Canada Morpho Sys Ag Transaction History

Royal Bank Of Canada

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$17.36 - $19.34 $2,222 - $2,475	-128 Reduced 64.0%	72 $1,000
Q1 2024 Nov 05, 2024	BUY	$8.6 - $18.18 $1,100 - $2,327	128 Added 177.78%	200 $3,000
Q2 2023 Aug 14, 2023	SELL	$3.95 - $7.74 $554,690 - $1.09 Million	-140,428 Reduced 99.86%	200 $1,000
Q1 2023 May 15, 2023	BUY	$3.56 - $5.22 $499,923 - $733,034	140,428 Added 70214.0%	140,628 $556,000
Q3 2021 Nov 15, 2021	BUY	$11.76 - $19.51 $2,352 - $3,902	200 New	200 $2,000

1.8M

14.7K

Ticker MOR
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 136,614,000
Description
MorphoSys AG, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic antibodies for patients suffering from cancer and autoimmune diseases in the United States. It offers Tafasitamab, an antibody for the treatment of B cell malignancies, including diffuse large B-cell lymphoma, f...

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

Stay updated on Royal Bank Of Canada with notifications on news.